Dr. Sartor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
Tulane UniversityResidency, Internal Medicine, 1983 - 1986
Childrens Hospital of PhiladelphiaInternship, Transitional Year, 1982 - 1983- Tulane University School of MedicineClass of 1982
Certifications & Licensure
NE State Medical License 2024 - 2026
LA State Medical License 1984 - 2025
MN State Medical License 2023 - 2025
MA State Medical License 2006 - 2009
MD State Medical License 1986 - 1993
PA State Medical License 1982 - 1983- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
- A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Publications & Presentations
PubMed
- 29 citationsDifferential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22 - 2358 citationsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialJohann S. de Bono, Stéphane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels
Lancet. 2010-10-02 - 144 citationsBiomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate CancerAndrew J. Armstrong, Mario A. Eisenberger, Susan Halabi, Stéphane Oudard, David M. Nanus
European Urology. 2012-03-01
Lectures
- VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive ...2019 ASCO Annual Meeting - 6/1/2019
- Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PRO...2019 ASCO Annual Meeting - 6/1/2019
- Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
